A campaigning doctor in the US has called on insurance companies to cover CBD treatments for patients.
Dr Sanjay Gupta, president of the American Pain Association (APA), said CBD could help with the USA’s opioid crisis by providing an alternative treatment widely considered not to be habit-forming or addictive.
“Given the choice between Oxycontin, Percocet and CBD, patients are more likely to choose the narcotics because they are covered by insurance companies and are affordable with co-pays or even free of charge,” Gupta said. “Insurance companies should be open to paying for patients who are willing to reduce opioid use by using CBD.”
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.
Do the Novel Food regulations in Europe affect your business?
CBD as a Novel Food: the future for edibles in Europe
This new CBD-Intel report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway.
Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.